ESMO 2020 Conference Highlights eBOOK
ESMO 2020 Lung Cancer Conference Report In Focus: Lung Cancer Durvalumab Demonstrates...
Dec 23, 2020
ESMO 2020 Lung Cancer Conference Report In Focus: Lung Cancer Durvalumab Demonstrates...
Nov 25, 2020
At the European Society for Medical Oncology (ESMO) Virtual Congress 2020 , lead study investigator Prof. Byoung Chul Cho (Yonsei Cancer Centre, Yonsei University College of Medicine in Seoul, South Korea) presented the interim...
Oct 27, 2020
At the ESMO Virtual Congress 2020 held 19-21 September, 2020, updated post-hoc findings from the...
Oct 21, 2020
Physician’s Weekly interviews principle investigator, Roy S. Herbst, MD, PhD, Ensign...
Sep 24, 2020
Lorlatinib is a third generation ALK tyrosine kinase inhibitor. The phase 3 CROWN study shows...
Sep 24, 2020
Several clinical trials have showed that combining an anti-CTLA-4 inhibitor and an anti-PD-(L)1...
Sep 24, 2020
PD-L1 expression is commonly used to predict response to immune checkpoint inhibitor therapy....
Sep 24, 2020
Patients with resectable non-small cell lung cancer (NSCLC) often develop (fatal) distant...
Sep 24, 2020
The merits of post-operative radiotherapy (PORT) in completely resected non-small cell lung cancer...
Sep 24, 2020
According the primary results of the COMBI-i trial, the addition of PD1 inhibitor spartalizumab to...
Sep 23, 2020
Sotorasib results promising in phase 1 trial Results of a 129-patient phase I trial of sotorasib,...
Sep 22, 2020
Efficacy observed for stage IB-IIIA disease Patients with resectable stage IB to III...